Runx2 is an essential transcription factor for osteoblast development and bone formation. It also contributes to T cell lymphomogenesis and breast cancer-associated osteolysis and skeletal disease. Runx2 is both an activator and represser of gene expression. Its activity is regulated by interactions with other proteins, including co-activators and co-repressors. Histone deacetylases (Hdacs) are among the co-repressors that associate with Runx2. We have identified four Hdacs (Hdac3, Hdac4, Hdac6, Hdac7) and the Hdac- associated co-repressor, mSinSA, as Runx2 interacting proteins. Our recent studies indicate that these interactions may be important for bone formation because Hdac inhibitors and Hdac3 shRNAs accelerate osteoblast maturation in vitro. Thus, we know the identity of several enzymes that negatively regulate Runx2 transcriptional activity, but we do not know what dictates their interactions with Runx2, whether they cooperate to modify Runx2 activity during bone formation, or if these co-repressors are important regulators of bone formation in vivo. Our next steps in pursuit of our long-term goal of understanding the molecular mechanisms whereby Runx2 regulates gene expression are to determine if Hdac3 delays osteoblast maturation in vivo as it does in vitro, to continue defining the multi-protein Runx2-repression complexes in vitro, and to begin identifying the molecular """"""""switches"""""""" that convert Runx2 from a represser to an activator by preventing its interactions with co-repressors. The objectives of this application are to determine how Hdac7 modifies Runx2 activity on its own, in cooperation with Hdac3 and in response to an osteogenic factor, and to determine if Hdac3 depletion accelerates osteoblast maturation and bone formation in vivo as it does in vitro. The central hypothesis of this study is that Hdac3 and Hdac7 are components of a multi-protein complex that regulates Runx2 activity and bone formation and is responsive to extracellular signals. The three specific aims we will pursue to test our hypothesis and accomplish the objectives of this application are to: 1) Define the role of Hdac3 in osteoblast maturation and bone formation in vivo, 2) Determine how Hdac7 regulates and interacts with Runx2, and 3) Identify stimuli and mechanisms that modify interactions between Runx2 and Hdac7 complexes. The proposed work is innovative because it will explore how multi-component represser complexes regulate Runx2 activity and determine how the co-repressors Hdac3 and Hdac7 contribute to bone formation in vivo and in vitro. These results will have collective impact because they are expected to define how Hdacs regulate Runx2 activity and osteoblast maturation. Our previous work indicates that Hdac inhibitors are potential anabolic agents. Thus, it is our expectation that this work will provide new perspectives and knowledge into treatment of bone formation disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR048147-09
Application #
7659562
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Sharrock, William J
Project Start
2001-12-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
9
Fiscal Year
2009
Total Cost
$309,835
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Bradley, Elizabeth W; Carpio, Lomeli R; Westendorf, Jennifer J (2013) Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem 288:9572-82
McGee-Lawrence, Meghan E; Li, Xiaodong; Bledsoe, Krista L et al. (2013) Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice. J Biol Chem 288:5291-302
McGee-Lawrence, Meghan E; Bradley, Elizabeth W; Dudakovic, Amel et al. (2013) Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone 52:296-307
Dudakovic, Amel; Evans, Jared M; Li, Ying et al. (2013) Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J Biol Chem 288:28783-91
Monroe, David G; McGee-Lawrence, Meghan E; Oursler, Merry Jo et al. (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492:1-18
Hoeppner, Luke H; Secreto, Frank J; Razidlo, David F et al. (2011) Lef1DeltaN binds beta-catenin and increases osteoblast activity and trabecular bone mass. J Biol Chem 286:10950-9
McGee-Lawrence, Meghan E; Westendorf, Jennifer J (2011) Histone deacetylases in skeletal development and bone mass maintenance. Gene 474:1-11
Undale, Anita; Fraser, Daniel; Hefferan, Theresa et al. (2011) Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. J Orthop Res 29:1804-11
Bradley, Elizabeth W; McGee-Lawrence, Meghan E; Westendorf, Jennifer J (2011) Hdac-mediated control of endochondral and intramembranous ossification. Crit Rev Eukaryot Gene Expr 21:101-13
McGee-Lawrence, Meghan E; McCleary-Wheeler, Angela L; Secreto, Frank J et al. (2011) Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 48:1117-26

Showing the most recent 10 out of 34 publications